AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...

Pramipexole, a Parkinson’s disease (PD) drug, impairs decision-making by hyperactivating the brain’s external globus pallidus ...

Annovis Bio saw promising results for Buntanetap in treating Alzheimer's and Parkinson's, but short cash runway prompts a ...

Parkinson's disease (PD), also known simply as Parkinson's, is a disorder of the nervous system that affects millions of ...

Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's disease and improved motor skills, the company reported on Thursday.

These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...

A new report sheds light on how a Parkinson’s disease drug may impair decision-making and lead to harmful behaviors like ...

Parkinson's is caused by the loss of neurons that produce dopamine, PPX binds to dopamine receptors in the brain.

Green Bay Packers quarterback, said he has the brain disorder Parkinson's disease, likely caused by countless concussions.

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...